betamethasone has been researched along with calcitriol in 303 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (1.32) | 18.7374 |
| 1990's | 11 (3.63) | 18.2507 |
| 2000's | 77 (25.41) | 29.6817 |
| 2010's | 147 (48.51) | 24.3611 |
| 2020's | 64 (21.12) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Berth-Jones, J; Fletcher, A; Hutchinson, PE | 1 |
| Clissold, SP; Murdoch, D | 1 |
| Long, CC; Marks, R | 1 |
| de Jong, EG; de Mare, S; van de Kerkhof, PC | 1 |
| Care, AD; Marshall, D; Maunder, EM; Pillay, AV; Ross, R; Sommerville, BA | 1 |
| Care, AD; Fox, J; Ross, R | 1 |
| Bernini, M; Fusi, L; Gennari, C; Montagnani, M; Nami, R; Nardi, P | 1 |
| Blahos, J; Care, AD; Sommerville, BA | 1 |
| Gniadecki, R; Serup, J | 1 |
| Scarpa, C | 1 |
| Kobayasi, T | 1 |
| Crosti, C; Finzi, AF; Mian, E; Scarpa, C | 1 |
| Barnes, L; Hamberg, KJ; Hutchinson, P; Kragballe, K; Murphy, F; Møller, S; Ruzicka, T; Van De Kerkhof, PC | 1 |
| Benelli, C; Cameli, N; Cannata, GE; Kokely, F; Piraccini, BM; Plozzer, C; Tosti, A | 1 |
| Erkko, P; Granlund, H; Lauerma, AI; Reitamo, S; Remitz, A | 1 |
| Hecker, D; Lebwohl, M; Worsley, J; Yueh, G | 1 |
| Pandey, SS; Reddy, DC; Singh, S | 1 |
| Goh, CL; Wong, SS | 1 |
| van de Kerkhof, PC; van Erp, PE; van Rossum, MM | 1 |
| Bibby, AJ; Buckley, C; Decroix, J; Douglas, WS; Gulliver, W; Iglesias, L; Krogstad, AL; Larsen, FG; Mrowietz, U; Ortonne, JP; Poulin, Y | 1 |
| Chu, AC; Garcia-Diez, A; Guenther, L; Kragballe, K; Snellman, E; Springborg, J; Tegner, E; Van de Kerkhof, PC | 1 |
| Poulin, Y | 1 |
| Bibby, AJ; Bissonnette, R; Cambazard, F; Chu, AC; Decroix, J; Douglas, WS; Kaufmann, R; Lowson, D; Mascaro, JM; Murphy, GM; Stymne, B | 1 |
| Fujii, Y; Mutoh, S; Ohkubo, Y; Sakuma, S; Takeuchi, H; Tanaka, K | 1 |
| Boyden, B; Burg, G; Chu, A; Guenther, L; Guilhou, JJ; Hanssen, LI; Harvima, RJ; Kaufmann, R; Larsen, FG; Papp, KA; Rogers, S; Talbot, D; Tegner, E; van de Kerkhof, PC | 1 |
| Camarasa, JM; Dubertret, L; Ortonne, JP | 1 |
| Hughes-Formella, BJ; Traulsen, J | 1 |
| Lui, H; Shapiro, J | 1 |
| Berends, M; de Jong, EM; Muys, L; van de Kerkhof, PC; van Erp, PE; Vissers, WH | 1 |
| Guenther, LC | 2 |
| Ortonne, JP | 1 |
| Hibon, JF | 1 |
| Cambazard, F | 1 |
| Estebaranz, JL; Fleming, C; Hanssen, LI; Kragballe, K; Lui, H; Noerrelund, KL; Ortonne, JP; Persson, LM; Uurasmaa, T; Wozel, G | 1 |
| Traulsen, J | 1 |
| van de Kerkhof, PC | 2 |
| Goodfield, M; Kaufmann, R; Lecha, M; Ortonne, JP | 1 |
| Didriksen, E; Hansen, J; Høy, G; Melchior, N; Persson, J; Simonsen, L | 1 |
| Fenton, C; Plosker, GL | 1 |
| Cambazard, F; Kragballe, K; Murray, S; van de Kerkhof, PC; Wasel, N | 1 |
| Deng, CH; Huang, X; Krochmal, L; Lenn, J; Tanojo, H | 1 |
| Guignard, E; Ortonne, JP; Peeters, P; Sitbon, R | 1 |
| Delvoye, P; Flagothier, C; Henry, F; Piérard, GE; Piérard-Franchimont, C | 1 |
| Chrysomallis, F; Kastanis, A; Lazaridou, E; Loannides, D; Vakirlis, E | 1 |
| Kragballe, K; van de Kerkhof, PC | 1 |
| Alhaddar, J; Duweb, G; Eljehawi, N; Elsherif, B; Makhlouf, H | 1 |
| Kaur, I; Kumar, B; Kumaran, MS | 1 |
| Charakida, A; Charakida, M; Chu, AC; Dadzie, O; Evangelou, G; Teixeira, F | 1 |
| Downs, AM | 1 |
| Flagothier, C; Henry, F; Piérard, GE; Piérard-Franchimont, C | 1 |
| Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Jolliffe, D; Kragballe, K; Peyri, J; Svensson, A; Toole, J; Wozel, G | 1 |
| Bibby, A; Cambazard, F; Foster, R; Haverkamp, C; Martinez Escribano, JA; Naeyaert, JM; Thaçi, D; Vender, R; White, S | 1 |
| Bovenschen, HJ; Erceg, A; Seyger, MM; van de Kerkhof, PC | 1 |
| Adriaans, B; Fergusson-Wood, LA; Griffiths, MR; Porter, W | 1 |
| Anstey, AV; Kragballe, K | 1 |
| Roebuck, HL | 1 |
| Altmeyer, P; Bräutigam, M; Brockmeyer, NH; Gambichler, T; Hyun, J; Kreuter, A; Sommer, A | 1 |
| Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Kragballe, K; Peyri Rey, J; Svensson, A; Toole, J; Williams, Z; Wozel, G | 1 |
| Bellino, M; Cassano, N; Coviello, C; Loconsole, F; Miracapillo, A; Vena, GA | 1 |
| Cassano, N; Vena, GA | 1 |
| Kragballe, K; Mrowietz, U; Segaert, S; van de Kerkhof, PC | 1 |
| Bovenschen, HJ; Erceg, A; Seyger, MM; Van De Kerkhof, PC; Van Vlijmen-Willems, I | 1 |
| Lebwohl, MG | 1 |
| Toole, JW | 1 |
| Dytoc, MT; Kossintseva, I; Ting, PT | 1 |
| Auland, ME; Bottomley, JM; Boyd, G; Douglas, WS; Morais, J | 1 |
| Augustin, M; Lapp, C; Moehling, U; Peeters, P; Radtke, M | 1 |
| Chrysomallis, F; Papagaryfallou, I; Patsatsi, A; Sotiriadis, D; Sotiriou, E | 1 |
| Andreassi, L; Ayala, F; Bongiorno, MR; Chimenti, S; Giannetti, A; Lisi, P; Martini, P; Peris, K; Peserico, A; Saraceno, R | 1 |
| Andreoli, GM; Calvieri, S; Cantisani, C; Cantisani, V; Cigna, E; Miller, DM; Scuderi, N; Solivetti, F | 1 |
| Buckley, C; Cambazard, F; Hoffmann, V; Milsgaard, M; Saari, S; Shapiro, J | 1 |
| Chen, CY; Chen, YH; Lo, PY; Tzung, TY; Yang, CY | 1 |
| Austad, J; Berne, B; Burden, AD; de Unamuno, P; Figueiredo, A; Ganslandt, C; Jemec, GB; Ortonne, JP; Poulin, Y | 1 |
| Assad, GB; Buggiani, G; De Giorgi, V; Delescluse, J; Hercogova, J; Lotti, T; Troiano, M | 1 |
| Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH | 1 |
| Gibney, J; Hughes, R; Kirby, B | 1 |
| Anstey, A; Barnes, L; Bolduc, C; Hoffmann, V; Reich, K; Saari, S; Segaert, S; Vaillant, L; van de Kerkhof, PC | 1 |
| Tsiskarashvili, NI; Tsiskarashvili, NV | 1 |
| Abramovits, W; Colón, LE; Gottschalk, RW; Johnson, LA; Menter, A | 1 |
| Avgerinou, G; Belyayeva, H; Daniel Iii, CR; Gregoriou, S; Katsambas, A; Kontochristopoulos, G; Larios, G; Rigopoulos, D; Stamou, C; Verra, P | 1 |
| Hoffmann, V; Kragballe, K; Nordin, P; Ortonne, JP; Segaert, S; Tan, J | 1 |
| Ganslandt, C; Kragballe, K; Nordin, P; Ortonne, JP; Segaert, S; Tan, J | 1 |
| Bordas, X; Borrego, L; Brufau, C; Caballé, G; Carrascosa, JM; Colomé, E; Fernández-López, E; Fuertes, A; Hernanz, JM; Herrera, E; Rodríguez-Fernández-Freire, L; Tuneu, A; Vanaclocha, F; Zulaica, A | 1 |
| Collins, P; Kirby, B; Langan, SM; Tobin, AM | 1 |
| Giovannini, A; Girolomoni, G; Gisondi, P; Rosina, P | 1 |
| Chimenti, S; Frascione, P; Gramiccia, T; Saraceno, R | 1 |
| Hagberg, O; Hoffmann, V; Kemp, K; Kvist, PH; Røpke, MA; Svensson, L | 1 |
| de Boer-van Huizen, RT; Otero, ME; Pasch, MC; van de Kerkhof, PC; van der Velden, HM; van Erp, PE; van Lingen, RG | 1 |
| Giannitelli, M; Lahfa, M; Livideanu, C; Maza, A; Meyer, N; Paul, C | 1 |
| Arenberger, P; Chimenti, S; Esslinger, HU; Ghislain, PD; Khemis, A; Kragballe, K; Kupper, H; Ortonne, JP; Saurat, JH; Sprøgel, P; Thaçi, D; Unnebrink, K | 1 |
| Belo, L; Castro, E; Coimbra, S; Figueiredo, A; Oliveira, H; Quintanilha, A; Reis, F; Rocha, S; Rocha-Pereira, P; Santos-Silva, A; Teixeira, F | 2 |
| Enevold, A; Ganslandt, C; Jemec, GB; van de Kerkhof, PC | 1 |
| Hino, R; Kabashima, R; Kawakami, C; Nakamura, M; Sugita, K; Tokura, Y | 1 |
| Augustin, M; Herberger, K; Kornek, T; Radtke, MA | 1 |
| Fleming, C; Ganslandt, C; Leese, GP | 1 |
| Kircik, LH; Kumar, S | 1 |
| Appell, M; Bibby, A; Foster, R; Hamilton, T; Lee, M; Mendoza, N; Tyring, S | 1 |
| de Peuter, R; Jansen, JP; Ryttov, J; van de Kerkhof, P | 1 |
| Freeman, K | 1 |
| Affleck, AG; Auland, M; Bottomley, JM; Jackson, P; Ryttov, J | 1 |
| Bottomley, JM; Ryttov, J; Taylor, RS | 1 |
| Chimenti, S; Gniadecki, R; Goldblum, O; Kupper, H; Ortonne, JP; Reich, K; Sprøgel, P; Thaçi, D; Unnebrink, K | 1 |
| Curčić, D; Gupta, A; Langley, RG; Papp, K; Wexler, D; Østerdal, ML | 1 |
| McCormack, PL | 2 |
| Murphy, G; Reich, K | 1 |
| Eicke, C; Macheleidt, O; Mrowietz, U | 1 |
| Cassano, N; Galluccio, A; Pezza, M; Vena, GA; Vestita, M | 1 |
| Calzavara-Pinton, P; Rossi, MT; Sala, R; Venturini, M | 1 |
| Kircik, LH | 1 |
| Bhutani, T; Busse, KL; Koo, J; Patel, T | 1 |
| Enevold, A; Ganslandt, C; Hoffmann, V; Queille-Roussel, C | 1 |
| Newman, MD; Silverberg, NB | 1 |
| Flores, R; Gottlieb, A; Levy, R; Liang, J; Punwani, N; Scherle, P; Shi, J; Williams, W; Yeleswaram, S | 1 |
| Li, W; Man, XY | 1 |
| Muro, M; Natsume, S; Okubo, Y; Tsuboi, R; Usui, K | 1 |
| Fischer, G; Hong, E; Kapila, S | 1 |
| Davis, SA; Feldman, SR; Koo, JY; Wong, JW | 1 |
| Xing, C; Xu, A | 1 |
| Caveney, SW; Gottschalk, RW; Menter, MA | 1 |
| Ayala, F; Cannavò, SP; Chimenti, S; De Pità, O; Girolomoni, G; Peserico, A; Vena, GA | 1 |
| Boyce, BM; Bukhalo, M; Ganslandt, C; Gold, LS; Grekin, S; Kempers, S; Lebwohl, M; Menter, A; Villumsen, J | 1 |
| Anger, T; Eicke, C; Sticherling, M | 1 |
| Akdeniz, N; Calka, O; Gunes Bilgili, S; Ozaydın Yavuz, G; Yavuz, IH | 1 |
| Hendriks, AG; Hondebrink, E; Seyger, MM; Steenbergen, W; van de Kerkhof, PC; van Hespen, JC | 1 |
| Calvieri, S; Camplone, G; Chimenti, S; D'Agostino, M; De Simone, C; Di Cesare, A; Filosa, G; Frascione, P; Gabellini, M; Lunghi, F; Mazzotta, A; Peris, K; Saraceno, R; Scotto Di Luzio, G; Simonacci, M | 1 |
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
| Höpfl, R; Huemer, HP; Martini, K; Müller, H | 1 |
| Abdelmaksood, R; Hashad, D | 1 |
| Jwa, SW; Kim, BS; Kim, HS; Kim, MB; Ko, HC; Mun, JH; Park, JM; Song, M | 1 |
| Clonier, F; Gupta, AK; Leeder, R; Olesen, M; Silver, S; Taraska, V; Tuppal, R | 1 |
| Ahn, CS; Awadalla, F; Dabade, TS; Feldman, SR; Huang, KE; Yentzer, B | 1 |
| Ropke, M; Segaert, S | 1 |
| Balkrishnan, R; Feldman, SR; Kakatkar, S; Levi, E; Pathak, P | 1 |
| Chimenti, S; Esposito, M; Frangione, V; Grodzińska, A; Kapińska-Mrowiecka, M; Naldi, L; Ortonne, JP | 1 |
| Hol, CW; Lambert, J; Vink, J | 2 |
| Cassano, N; Neri, L; Vena, GA | 1 |
| de Jong, EM; Mul, K; Oostveen, AM; Seyger, MM; van de Kerkhof, PC; van Geel, MJ | 1 |
| Jellinek, NJ; Vélez, NF | 1 |
| Kim, HS; Kim, MB; Park, JM | 1 |
| Kragballe, K; van de Kerkhof, P | 1 |
| Bewley, A; Cambazard, F; Daudén, E; Girolomoni, G; Lambert, J; Reich, K | 1 |
| Debarre, JM; Gooderham, M; Goodfield, M; Keddy-Grant, J; Kurvits, M; Xu, Z | 1 |
| Descargues, P; Dünstl, G; Gonzalez, T; Kurdykowski, S; Marstrand, T; Norsgaard, H; Røpke, M | 1 |
| Ardabili, M; Augustin, M; Bonnekoh, B; Mrowietz, U; Reich, K; Reusch, M; Rosenbach, T; Thaçi, D | 1 |
| Guo, XF; Li, G; Li, XY; Lu, CJ; Ou, AH; Wen, ZH; Xuan, ML; Yan, YH; Yao, DN | 1 |
| Agrawal, S; Harde, H; Jain, S; Katariya, M; Sonawane, R | 1 |
| Clonier, F; Olesen, M; Queille-Roussel, C | 1 |
| Cantrell, W; Elewski, B; Kole, L | 1 |
| Del Rosso, JQ | 1 |
| de Jong, EM; Donders, AR; Oostveen, AM; Seyger, MM; van de Kerkhof, PC | 1 |
| Bachelez, H; de Jong, EM; Gisondi, P; Mrowietz, U; Puig, L; Reich, K; Warren, RB; Zschocke, I | 1 |
| Hendriks, AG; Joosten, I; Keijsers, RR; Koenen, HJ; van de Kerkhof, PC; van Erp, PE | 1 |
| Miracapillo, A; Neri, L | 1 |
| de Jonge, CS; Hendriks, AG; Lucas, M; Seyger, MM; Steenbergen, W; van de Kerkhof, PC | 1 |
| Clark, A; Feldman, SR; Harrison, J; Huang, KE; Sandoval, LF | 1 |
| Bagel, J; Knuckles, ML; Levi, E; Tyring, S | 1 |
| Glick, BP; Touloei, K; Wiener, A | 1 |
| Lacour, JP; Olesen, M; Queille-Roussel, C; Villumsen, J | 1 |
| Annessi, G; Boccaletti, V; Cortelazzi, C; Di Nuzzo, S; Fabrizi, G; Fantini, C; Feliciani, C; Pagliarello, C; Zampetti, A | 1 |
| Cui, P; Facy, P; Gao, T; Ge, M; Gu, J; Hao, F; Kurvits, M; Li, R; Ma, L; Sun, Q; Wang, G; Xu, J; Xu, Z; Yang, H; Yang, Q; Zheng, M | 1 |
| Bang Pedersen, C; Olesen, M; Papp, K; Taraska, V; Tuppal, R | 1 |
| Bagel, J; Bruce, S; Koo, J; Olesen, M; Tyring, S; Villumsen, J; Werschler, WP | 1 |
| Gual, A; Molin, S; Pau-Charles, I | 1 |
| Bagel, J; Leonardi, C; Olesen, M; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P; Østerdal, ML | 1 |
| Lovato, P; Norsgaard, H; Røpke, MA; Tokura, Y | 1 |
| Nissen, CV; Philipsen, PA; Wiegell, SR; Wulf, HC | 1 |
| Einecke, D | 1 |
| Deng, JW; Guo, XF; He, ZH; Li, G; Li, XY; Lu, CJ; Ou, AH; Wen, ZH; Xie, XL; Xuan, ML; Yan, YH; Yao, DN | 1 |
| Stein Gold, LF | 1 |
| Feldman, SR; Hill, D; Kin, KC | 1 |
| Aoi, N; Harada, Y; Kaneko, S; Morita, E; Murata, S | 1 |
| Chantzaras, A; Kontochristopoulos, G; Kouris, A; Petridis, A; Yfantopoulos, J | 1 |
| Larsen, LS; Lophaven, KW; McHorney, CA; Moeller, AH; Pedersen, CB; Reaney, M | 1 |
| Chokoeva, AA; Ivanova, B; Mangarov, H; Tchernev, G; Vidolova, NG | 1 |
| Bang, B; Cambazard, F; Griffiths, CE; Kalb, RE; Lowson, D; Paul, C; Stein Gold, L | 1 |
| Koo, J; Lebwohl, M; Menter, A; Rosen, M; Stein Gold, L; Villumsen, J | 1 |
| Bagel, J; Leonardi, C; Moller, A; Osterdal, ML; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P | 1 |
| Clark, M; Copley-Merriman, C; Gnanasakthy, A; Zelt, S | 1 |
| Frampton, JE; Kim, ES | 1 |
| Li, G; Lu, C; Lu, L; Wen, Z; Xuan, M; Yan, Y; Zhou, L | 1 |
| Choe, YB; Choi, JH; Kim, KJ; Kim, NI; Kim, TY; Lee, JH; Park, CJ; Song, HJ; Youn, JI; Youn, SW | 1 |
| Glumoff, V; Haapasaari, KM; Hägg, PM; Hurskainen, T; Kokkonen, N; Kubin, ME; Palatsi, R; Tasanen, K; Väyrynen, JP | 1 |
| Bang, B; Lebwohl, M; Paul, C | 1 |
| Calzavara Pinton, P; Cicchetti, A; Cristaudo, A; Girolomoni, G | 1 |
| Clonier, F; Lacour, JP; Nørremark, K; Queille-Roussel, C; Rosen, M | 1 |
| Arango-Duque, LC; Fernández López, E; Palacios Álvarez, I; Roncero-Riesco, M; Usero Bárcena, T | 1 |
| Gold, LS; Lebwohl, M; Leonardi, C; Menter, A; Møller, A; Paul, C; Reich, K; Warren, RB | 1 |
| Bachelez, H; de Jong, EMGJ; Gisondi, P; Mrowietz, U; Ortland, C; Puig, L; Reich, K; Warren, RB; Zschocke, I | 1 |
| Croney, S | 1 |
| Iizuka, H; Satoh, K; Takagi, A; Takahashi, H | 1 |
| Ansaripour, A; Maessen, R; Redekop, WK; Thio, HB | 1 |
| Caldarola, G; De Simone, C; Moretta, G; Peris, K; Poscia, A | 1 |
| Chantzaras, A; Kontodimas, S; Yfantopoulos, J | 1 |
| Asche, CV; Feldman, SR; Kim, M; Lu, M; Zografos, P | 1 |
| Akiyama, M; Kojima, D; Kono, M; Okuno, Y; Suga, Y; Takeichi, T; Tsukamoto, K | 1 |
| Frieder, J; Kivelevitch, D; Menter, A | 1 |
| Hägg, PM; Kubin, ME; Pääkkö, TJW; Palatsi, R; Tasanen, K | 1 |
| Borghi, A; Conti, A; Gisondi, P; Manfredini, S; Pazzaglia, M; Piaserico, S; Stinco, G; Venturini, M | 1 |
| Bulai Livideanu, C; Kaldate, R; Paul, C; Røpke, M; Snel, A | 1 |
| Hong, CH; Lophaven, KW; Papp, KA; Philipp, S; Skallerup, P | 1 |
| Goldenberg, G; Hashim, PW; Kircik, LH; Nia, JK; Terrano, D | 1 |
| Ikumi, K; Kubo, R; Morita, A; Muramatsu, S; Nishida, E; Sagawa, Y; Saito, C; Torii, K | 1 |
| Barker, RN; Kotb, IS; Lewis, BJ; Ormerod, AD | 1 |
| Foley, P; Garrett, S; Ryttig, L | 1 |
| Andersen, F; Andersen, KE; Andersen, KH; Svendsen, MT | 1 |
| Anger, T; Gerdes, S; Hutt, HJ; Körber, A; Krakor, M | 1 |
| Andersen, F; Andersen, KE; Andersen, KH; August, B; Feldman, SR; Johannessen, H; Möller, S; Pottegård, A; Svendsen, MT | 1 |
| Bohdanowicz, M; DeKoven, JG | 1 |
| Grabnar-Peklar, D; Habjanic, N; Kerec-Kos, M; Koytchev, R; Yankova, R | 1 |
| Cambazard, F; Griffiths, CE; Kalb, RE; Lowson, D; Møller, A; Paul, C; Stein Gold, L | 1 |
| Al-Shenawy, HA; Elgendy, HY; Hassan, GF; Ibrahim, ZA | 1 |
| Carretero, G; Puig, L | 1 |
| Adamski, Z; Bowszyc-Dmochowska, M; Dańczak-Pazdrowska, A; Gaura, T; Olek-Hrab, K; Osmola-Mańkowska, A; Polańska, A; Żaba, R | 1 |
| Kuehl, B; Shear, NH | 1 |
| Bagel, J; Nelson, E; Zapata, J | 1 |
| Cantrell, W; Gooding, K; Gorelick, J; Kucera, K; Veverka, KA | 1 |
| Fu, L; Gao, XH; Jin, H; Li, R; Li, X; Lin, Z; Liu, Y; Lu, Q; Wang, Y; Xia, L; Xiao, F; Yang, S; Zhang, J; Zhang, X; Zheng, J | 1 |
| Giacomelli, L; Giovene, GL | 1 |
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Andersen, SB; Berg, P; Calzavara-Pinton, PG; de la Cueva Dobao, P; Jalili, A; Jensen, KL; Lebwohl, M; Pink, AE; Segaert, S; Stein Gold, L; Thaçi, D | 1 |
| El-Mosallamy, SS; El-Zeany, BA; Hassan, NY; Merey, HA | 1 |
| Duvetorp, A; Engerstedt Mattsson, E; Levin, LÅ; Ryttig, L | 1 |
| Lee, EB; Pithadia, DJ; Reynolds, KA; Wu, JJ | 1 |
| Andersen, KE; Feldman, SR; Möller, S; Svendsen, MT | 1 |
| Balato, A; Caterino, P; Cirillo, T; Dente, V; Gallo, L; Lodi, G; Megna, M; Mozzillo, R | 1 |
| Berg, P; Calzavara-Pinton, PG; de la Cueva Dobao, P; Jalili, A; Jensen, KL; Pink, AE; Segaert, S; Thaçi, D; Torpet, M | 1 |
| Yap, FB | 1 |
| Del Rosso, JQ; Kircik, LH | 1 |
| Deng, H; Deng, J; Lu, C; Wen, Z; Xiang, Y; Xuan, M; Yan, Y; Yao, D | 1 |
| Grabnar Peklar, D; Habjanič, N; Kerec-Kos, M; Lužar-Stiffler, V | 1 |
| de Gannes, G; Dutz, J; Han, C; Piesik, P | 1 |
| Eichenfield, LF; Kurvits, M; Liljedahl, M; Marcoux, D | 1 |
| Fukaya, S; Fukuyasu, A; Hau, CS; Hayashi, K; Ishikawa, T; Kamata, M; Ohnishi, T; Shimizu, T; Tada, Y; Takeoka, S; Tanaka, T | 1 |
| Bennardo, L; Bianchi, L; Dastoli, S; Dattola, A; Nisticò, SP; Passante, M; Patruno, C; Rizzuto, F; Silvestri, M | 1 |
| He, Z; Liu, Y; Wang, T; Yang, L; Zdravković, TP; Zhang, S | 1 |
| Antunes, J; Balak, DMW; Becla, L; Bewley, A; Calzavara-Pinton, P; Carrascosa, JM; Gregoriou, S; Nyeland, ME; Sawyer, LM; Viola, MG | 1 |
| Ahn, JY; Bae, JY; Jang, DH; Jung, HJ; Lee, JI; Park, MY | 1 |
| Gerdes, S; Hubo, M; Velasco, M; Veverka, KA; Wu, JJ | 1 |
| Habjanič, N; Kerec Kos, M; Kristan, K | 1 |
| Abramovits, W; Hoejen, MN; Liljedahl, M; Seyger, M; Teng, J | 1 |
| Anger, T; Del Rosso, J; Hansen, B; Kircik, LH; Patel, DS; Veverka, KA | 1 |
| Amano, H; Mori, S; Tamai, K | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Gregoriou, S; Kostakis, P; Panagakis, P; Polydorou, D; Rigopoulos, D; Rompoti, N; Sidiropoulou, P; Tsimpidakis, A; Tsironi, T | 1 |
| Alejo, B; Domínguez, M; Ertekin, SS; Herrero, A; Iglesias, P; Malvehy, J; Martinez, N; Puig, S; Villa-Crespo, L; Yélamos, O; Zamora-Barquero, S | 1 |
| Bewley, A; Dauden, E; Fabbrocini, G; Jalili, A | 1 |
| Gold, LS; Hansen, JB; Patel, D; Strober, B; Veverka, KA | 1 |
| Camela, E; Cinelli, E; Fabbrocini, G; Megna, M | 1 |
| Bianchi, L; Dattola, A; Ferrari, D; Floris, R; Guazzaroni, M; Lamacchia, F; Marisi, V; Marsico, S; Orlacchio, A; Tatulli, D | 1 |
| Alves, J; António, AM; Bártolo, E; Bonito, F; Cerejeira, D | 1 |
| Hagiwara, M; Katayama, H; Koda, M; Matsuo, K; Nakagawa, H; Sasaki, H; Takahashi, H; Tanito, K; Uwajima, Y | 1 |
| Ashizawa, S; Hide, M; Takahagi, S; Tanaka, A | 1 |
| Lebwohl, M; Petersen, B | 1 |
| Alonso-Llamazares, J; Cantrell, W; Kircik, L; Koo, J; Moore, A; Stein Gold, L; Teng, J | 1 |
| Gold, LS; Kircik, L; Lacour, JP; Lebwohl, M; Liljedahl, M; Lynde, C; Mørch, MH; Papp, KA; Perrot, JL; Takhar, A; Thaçi, D; Warren, RB; Wollenberg, A | 1 |
| Kircik, LH; Schlesinger, TE; Tanghetti, E | 1 |
| Abramovits, W; Gupta, AK; Teng, JMC; Vincent, KD | 1 |
| Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ | 1 |
| Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T | 1 |
| Cao, S; Chen, K; Chen, Y; Cheng, H; Ding, Y; Fang, H; Han, X; He, L; He, Y; Huang, J; Li, M; Li, S; Li, W; Liu, L; Lu, Q; Lu, Y; Pan, W; Wang, J; Yan, G; Zhang, C; Zhang, J; Zheng, M; Zhu, W | 1 |
| Di Guida, A; Fabbrocini, G; Napolitano, M; Patruno, C | 1 |
| Bagel, J; Hetzel, A; Nelson, E; Riley, C | 1 |
| Abd Elazim, NE; Abdel Gaber, RM; El-Deek, HEM; Fathy, E; Kamal, A | 1 |
| Paul, C; Romiti, R; Stein Gold, L | 1 |
| Jalili, A; Yosipovitch, G | 1 |
| Iversen, L; Koo, J; Tada, Y | 1 |
| Armstrong, A; Gerdes, S | 1 |
| Lebwohl, M; Warren, RB | 1 |
| Chasapi, V; Cheliotis, G; Georgiou, S; Ioannides, D; Lazaridou, E; Papadavid, E; Rigopoulos, D; Sfaelos, K | 3 |
| Balogh, EA; Feldman, SR; Heron, CE; Purvis, CG | 1 |
| Artzi, O; Ellenbogen, E; Matz, H; Shehadeh, W; Sprecher, E | 1 |
| Dhawan, S; Green, LJ; Praestegaard, M; Selmer, J; Stein Gold, L; Vestbjerg, B | 1 |
| Gold, M; Gooderham, M; Kircik, LH; Lacour, JP; Laws, P; Liljedahl, M; Lynde, C; Mørch, MH; Sondermann, W; Thaçi, D; Warren, RB | 1 |
| Nyholm, N; Petersen, B; Stein Gold, L; Takhar, A; Thoning, H | 1 |
| Asahina, A; Asawanonda, P; Frez, ML; Hyun Kim, D; Imafuku, S; Theng, C; Wang, L; Zhang, JA; Zhao, Y; Zimmo, S | 1 |
| Gooderham, M; Harvima, RJ; Nyholm, N; Stein Gold, L; Thoning, H; Tyring, S | 1 |
| Argenziano, G; Atzori, L; Bianchi, L; Campanati, A; Corazza, M; Damiani, G; De Pità, O; Donini, M; Fargnoli, MC; Feliciani, C; Mazzatenta, C; Mazzotta, A; Offidani, A; Peris, K; Potenza, C; Prignano, F; Stingeni, L; Tiberio, R | 1 |
| Adamski, Z; Guenther, L; Lacour, JP; Liljedahl, M; Lynde, C; Miasik-Pogodzinska, A; Mørch, MH; Nutt, T; Papp, K; Reich, A; Sadick, N; Szponar-Bojda, A; Turchin, I; Tyring, S; Werschler, W | 1 |
| Hansen, JB; Kircik, L; Stein Gold, L; Veverka, KA; Yaloumis, M | 1 |
| Ding, H; Dong, S; Feng, J; Li, N; Li, X; Ren, J; Sun, Z; Wang, H; Wang, S; Zhu, Q | 1 |
| Augustin, M; Gold, LS; Green, LJ; Pinter, A; Praestegaard, M; Selmer, J | 1 |
| Calzavara-Pinton, P; Dapavo, P; De Simone, C; Fabbrocini, G; Malagoli, P; Martella, A | 1 |
| Bagel, J; Nelson, E | 1 |
| Armstrong, A; Koo, J; Pinter, A; Præstegaard, M; Reich, A; Selmer, J | 1 |
| Kircik, L; Ozyurekoglu, E | 1 |
| Czerwińska, J; Kasprowicz-Furmańczyk, M; Owczarczyk-Saczonek, A; Placek, W | 1 |
| Avey, B; Baker, H; Barker, E; Bewley, A; Galván, J; Green, W; Pi-Blanque, A; Praestegaard, M; Trebbien, P | 1 |
| Cardot-Leccia, N; Duteil, L; Heim, M; Irondelle, M; Passeron, T; Rocchi, S; Tulic, MK | 1 |
| Abdel Raouf, NM; El Sharkawy, DA; El-Komy, MHM; Fahim, A; Sobhi, RM | 1 |
| Arenberger, P; Armstrong, A; Augustin, M; Gold, LS; Iversen, L; Pinter, A; Praestegaard, M; Reich, A | 1 |
| Armstrong, AW; Khan, S; Kircik, L; Reddy, R | 1 |
43 review(s) available for betamethasone and calcitriol
| Article | Year |
|---|---|
Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris.
Topics: Anthralin; Betamethasone; Calcitriol; Calcium; Cell Differentiation; Cell Division; Combined Modality Therapy; Humans; Psoriasis; Randomized Controlled Trials as Topic | 1992 |
Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Glucocorticoids; Humans; Ointments; Psoriasis | 2002 |
Fixed-dose combination therapy for psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index | 2004 |
[Clinical experience with Daivobet].
Topics: Betamethasone; Calcitriol; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Psoriasis; Severity of Illness Index; Treatment Outcome | 2004 |
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
A novel foam vehicle for delivery of topical corticosteroids.
Topics: Administration, Cutaneous; Administration, Topical; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Betamethasone; Body Water; Calcitriol; Clindamycin; Clobetasol; Dermatologic Agents; Dosage Forms; Hot Temperature; Humans; Ketoconazole; Ointments; Pharmaceutical Vehicles; Skin; Skin Absorption | 2005 |
[The calcipotriol-betamethasone dipropionate association].
Topics: Administration, Topical; Betamethasone; Calcitriol; Drug Therapy, Combination; Humans; Inflammation; Psoriasis | 2005 |
Calcipotriol/betamethasone dipropionate for the treatment of psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Synergism; Humans; Keratinocytes; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
[How I treat...topical treatment of plaque type psoriasis by the combination of calcipotriol and betamethasone dipropionate].
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Psoriasis | 2006 |
Newer treatment options for patients with moderate-to-severe psoriatic disease.
Topics: Adalimumab; Alefacept; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Attitude to Health; Betamethasone; Body Image; Calcitriol; Clobetasol; Dermatologic Agents; Diagnosis, Differential; Drug Monitoring; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index | 2006 |
Calcipotriene/betamethasone in the treatment of psoriasis: a review article.
Topics: Betamethasone; Calcitriol; Cell Differentiation; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Keratinocytes; Psoriasis; Treatment Outcome | 2009 |
[Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Gels; Humans; Incidence; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2010 |
Scalp psoriasis.
Topics: Betamethasone; Calcitriol; Clobetasol; Coal Tar; Drug Combinations; Glucocorticoids; Humans; Keratolytic Agents; Psoriasis; Scalp Dermatoses | 2010 |
Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.
Topics: Administration, Topical; Adult; Algorithms; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome | 2011 |
Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Models, Econometric; Psoriasis; Scalp Dermatoses; Scotland; Severity of Illness Index; Treatment Outcome | 2011 |
The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence.
Topics: Administration, Topical; Algorithms; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Evidence-Based Practice; Gels; Humans; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2011 |
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
Topics: Back; Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Extremities; Gels; Humans; Ointments; Psoriasis; Scalp; Thorax; Treatment Outcome | 2011 |
In touch with psoriasis: topical treatments and current guidelines.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Humans; Practice Guidelines as Topic; Psoriasis | 2011 |
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Extremities; Gels; Humans; Ointments; Psoriasis; Scalp; Torso | 2011 |
Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Clobetasol; Drug Combinations; Glucocorticoids; Humans; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Scalp; Severity of Illness Index; Treatment Outcome | 2012 |
Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Gels; Humans; Medication Adherence; Ointments; Psoriasis | 2014 |
Solitary morphea profunda following trauma sustained in an automobile accident.
Topics: Accidents, Traffic; Anti-Inflammatory Agents; Antirheumatic Agents; Arm Injuries; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Middle Aged; Prednisone; Scleroderma, Localized | 2015 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Nicotinic Acids; Patient Compliance; Pharmaceutical Vehicles; Practice Guidelines as Topic; Psoriasis; Quality of Life; Severity of Illness Index; Tacrolimus; Treatment Outcome; Vitamin D | 2016 |
Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2016 |
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Quality of Life; Self Report; Skin Diseases; Surveys and Questionnaires | 2017 |
Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Quality of Life | 2016 |
Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Ointments; Psoriasis; Quality of Life; Treatment Outcome | 2017 |
Back to the future: a new topical approach for mild-to-moderate psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Phototherapy; Psoriasis; Severity of Illness Index; Skin Absorption; Treatment Outcome | 2018 |
Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life | 2017 |
How to improve adherence to treatment in patients with mild-to-moderate psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Medication Adherence; Patient Satisfaction; Physician-Patient Relations; Psoriasis; Severity of Illness Index | 2018 |
Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam.
Topics: Administration, Topical; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Psoriasis | 2019 |
The Evolution of Topical Formulations in Psoriasis.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Randomized Controlled Trials as Topic | 2018 |
Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Biological Availability; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Italy; Psoriasis; Skin Absorption; Treatment Outcome | 2018 |
Psoriasis-associated itch: etiology, assessment, impact, and management.
Topics: Betamethasone; Calcitriol; Cost of Illness; Dermatologic Agents; Humans; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index | 2020 |
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Congresses as Topic; Dosage Forms; Drug Combinations; Humans; Medication Adherence; Psoriasis | 2020 |
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis | 2020 |
Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Biological Products; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Humans; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
Clinical efficacy and safety of using calcipotriol-betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2022 |
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
Topics: Betamethasone; Calcitriol; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2022 |
123 trial(s) available for betamethasone and calcitriol
| Article | Year |
|---|---|
Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate.
Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Betamethasone; Calcitriol; Dendritic Cells; Epidermis; Female; Humans; Keratins; Male; Middle Aged; Psoriasis; T-Lymphocytes | 1992 |
Calcipotriol and betamethasone valerate for psoriasis.
Topics: Betamethasone; Calcitriol; Double-Blind Method; Humans; Psoriasis | 1991 |
DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone.
Topics: Adult; Aged; Antibodies, Monoclonal; Betamethasone; Calcitriol; DNA; Double-Blind Method; Female; Fluorescent Antibody Technique; Humans; Keratins; Male; Middle Aged; Psoriasis; Skin | 1990 |
Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Psoriasis; Salicylates; Salicylic Acid | 1994 |
Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Patient Compliance; Psoriasis; Salicylates; Salicylic Acid; Treatment Outcome | 1997 |
Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Psoriasis; Treatment Outcome | 1998 |
Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Salicylates | 1998 |
Tacrolimus ointment improves psoriasis in a microplaque assay.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Ointments; Psoriasis; Skin Tests; Statistics, Nonparametric; Tacrolimus | 1999 |
Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Single-Blind Method; Treatment Outcome | 2000 |
Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis.
Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Dermatologic Agents; Double-Blind Method; Female; Glucocorticoids; Humans; Leg Dermatoses; Male; Middle Aged; Ointments; Prurigo | 2000 |
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.
Topics: Adult; Aged; Betamethasone; Calcitriol; Cell Cycle; Cell Division; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Flow Cytometry; Humans; Keratin-10; Keratins; Male; Middle Aged; Psoriasis; Skin; Vimentin | 2001 |
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Psoriasis | 2002 |
Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis | 2002 |
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Psoriasis; Reference Values; Severity of Illness Index; Sweden; Treatment Outcome | 2002 |
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
Topics: Adolescent; Betamethasone; Calcitriol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Pharmaceutical Vehicles; Prospective Studies; Psoriasis; Treatment Outcome | 2003 |
Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2003 |
The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment.
Topics: Adult; Atrophy; Betamethasone; Biopsy, Needle; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Skin; Ultrasonography | 2003 |
The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis.
Topics: Anti-Inflammatory Agents; Antigens, CD; Betamethasone; Calcitriol; Cell Division; Dermis; Drug Therapy, Combination; Epidermis; Humans; Keratins; Ointments; Psoriasis; Skin; T-Lymphocyte Subsets; T-Lymphocytes | 2004 |
Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Canada; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Severity of Illness Index | 2004 |
The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial.
Topics: Activities of Daily Living; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Disability Evaluation; Double-Blind Method; Drug Combinations; Female; Health Status Indicators; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Treatment Outcome | 2004 |
Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Confidence Intervals; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Prospective Studies; Psoriasis; Reference Values; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Confidence Intervals; Cost-Benefit Analysis; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Costs; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Probability; Psoriasis; Reference Values; Risk Factors; Severity of Illness Index; Treatment Outcome | 2005 |
Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris.
Topics: Adolescent; Adult; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis | 2005 |
Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Ointments; Severity of Illness Index; Treatment Outcome; Vitiligo | 2006 |
Dovobet ointment under occlusion overnight for troublesome scalp psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2006 |
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Eruptions; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index | 2006 |
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chi-Square Distribution; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Treatment Outcome | 2006 |
Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Humans; Laser Therapy; Male; Middle Aged; Psoriasis; Treatment Outcome | 2006 |
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
Topics: Alefacept; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Ointments; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index | 2006 |
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcineurin Inhibitors; Calcitriol; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptidylprolyl Isomerase; Psoriasis; Severity of Illness Index; Tacrolimus; Treatment Outcome | 2006 |
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Safety; Time Factors; Treatment Outcome | 2006 |
Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Pilot Projects; Pruritus; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Germany; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Models, Theoretical; Psoriasis | 2007 |
Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2007 |
Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Satisfaction; Probability; Prospective Studies; Psoriasis; Reference Values; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2008 |
Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Nail Diseases; Psoriasis; Severity of Illness Index; Single-Blind Method | 2008 |
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Skin; Treatment Outcome | 2008 |
A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Canada; Denmark; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; France; Germany; Humans; Male; Middle Aged; Ointments; Pharmaceutical Vehicles; Prospective Studies; Psoriasis; Scalp; Severity of Illness Index; Treatment Outcome; United Kingdom | 2008 |
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Drug Administration Schedule; Drug Combinations; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome; Young Adult | 2009 |
[New perspectives in treatment of bounded forms of psoriasis].
Topics: Adolescent; Adult; Betamethasone; Calcitriol; Combined Modality Therapy; Drug Combinations; Electronarcosis; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Treatment Outcome; Young Adult | 2008 |
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Psoriasis; Quality of Life | 2009 |
Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Nail Diseases; Ointments; Psoriasis | 2009 |
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Young Adult | 2009 |
Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Psychology; Quality of Life; Scalp Dermatoses; Single-Blind Method; Treatment Outcome; Young Adult | 2009 |
Microcirculatory modifications of psoriatic lesions during topical therapy.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Capillaries; Dermatologic Agents; Dermoscopy; Drug Therapy, Combination; Female; Humans; Male; Microcirculation; Microscopic Angioscopy; Middle Aged; Psoriasis; Skin; Treatment Outcome; Young Adult | 2009 |
Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model.
Topics: Animals; Betamethasone; Biomarkers; Biopsy; Calcitriol; Dermatologic Agents; Disease Models, Animal; Drug Combinations; Endpoint Determination; Humans; Immunohistochemistry; Mice; Mice, SCID; Psoriasis; Skin; Skin Tests; Transplantation, Heterologous; Vitamin D | 2009 |
Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study.
Topics: Adolescent; Adult; Betamethasone; Biomarkers; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Epithelium; Humans; Psoriasis; Treatment Outcome; Young Adult | 2010 |
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Topics: Adalimumab; Administration, Topical; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Male; Medication Adherence; Middle Aged; Psoriasis; Severity of Illness Index | 2010 |
Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Scalp; Young Adult | 2011 |
Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Ointments; Pituitary-Adrenal System; Prospective Studies; Psoriasis; Time Factors; Young Adult | 2010 |
A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Black or African American; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Hispanic or Latino; Humans; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
Topics: Adalimumab; Administration, Topical; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Tumor Necrosis Factor-alpha | 2011 |
Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Dihydroxycholecalciferols; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Ointment Bases; Pharmaceutical Vehicles; Psoriasis; Severity of Illness Index; Treatment Outcome | 2011 |
Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pilot Projects; Psoriasis; Severity of Illness Index; Young Adult | 2012 |
The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Budesonide; Calcitriol; Dermatologic Agents; Dihydroxycholecalciferols; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Psoriasis; Time Factors; Young Adult | 2011 |
Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Calcitriol; Contraceptives, Oral, Combined; Dermatologic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Tumor Necrosis Factor; Sample Size; Treatment Outcome | 2011 |
Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Male; Middle Aged; Occlusive Dressings; Ointments; Psoriasis; Single-Blind Method; Treatment Outcome | 2011 |
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Nitriles; Pilot Projects; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Treatment Outcome; Young Adult | 2012 |
Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Skin Cream | 2014 |
The effect of combined calcipotriol and betamethasone dipropionate ointment in the treatment of vitiligo: an open, uncontrolled trial.
Topics: Acne Vulgaris; Adolescent; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Eruptions; Female; Humans; Male; Middle Aged; Ointments; Photography; Pruritus; Time Factors; Treatment Outcome; Vitiligo; Young Adult | 2012 |
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Endpoint Determination; Female; Humans; Immunoglobulin A; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis; Quality of Life; Skin; Suspensions | 2013 |
Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet® Gel) and improvement of quality of life in patients with psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Germany; Humans; Male; Middle Aged; Patient Satisfaction; Prevalence; Psoriasis; Quality of Life; Risk Factors; Treatment Outcome | 2013 |
Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Male; Middle Aged; Treatment Outcome; Ultraviolet Therapy; Vitiligo; Young Adult | 2014 |
Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients.
Topics: Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Psoriasis; Recurrence; Scalp Dermatoses; Young Adult | 2014 |
Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: an open-label study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Ointments; Onycholysis; Severity of Illness Index; Young Adult | 2013 |
Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Calcium; Creatinine; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Psoriasis; Severity of Illness Index; Suspensions; Time Factors | 2013 |
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial.
Topics: Anti-Inflammatory Agents; Bandages; Betamethasone; Betamethasone Valerate; Calcitriol; Chronic Disease; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Single-Blind Method | 2014 |
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Gels; Humans; Male; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2014 |
Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial.
Topics: Betamethasone; Calcitriol; Clinical Protocols; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Ointments; Outcome Assessment, Health Care; Psoriasis | 2014 |
Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Gels; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2014 |
A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Nail Diseases; Ointments; Psoriasis; Treatment Outcome | 2014 |
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.
Topics: Administration, Cutaneous; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Patient Preference; Prospective Studies; Psoriasis; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Biomarkers; Blood Flow Velocity; Calcitriol; Cytokines; Dermatologic Agents; Drug Combinations; Female; Humans; Laser-Doppler Flowmetry; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Ointments; Perfusion Imaging; Psoriasis; Reproducibility of Results; Sensitivity and Specificity; Skin; Up-Regulation | 2015 |
Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Patient Preference; Pilot Projects; Psoriasis; Severity of Illness Index; Suspensions; Treatment Outcome | 2014 |
Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Topics: Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Single-Blind Method; Ultrasonography; Young Adult | 2015 |
Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population.
Topics: Administration, Topical; Adult; Asian People; Betamethasone; Calcitriol; China; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Safety; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Solutions; Treatment Outcome | 2016 |
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Single-Blind Method; Treatment Outcome | 2016 |
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Psoriasis; Skin; Treatment Outcome; Young Adult | 2015 |
Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Feasibility Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Quality of Life; Recurrence; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2016 |
Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospective Studies; Pruritus; Psoriasis; Treatment Outcome; Visual Analog Scale; Young Adult | 2017 |
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Female; Gels; Humans; Male; Middle Aged; Psoriasis | 2017 |
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Drug Combinations; Drug Compounding; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Statistics as Topic; Treatment Outcome; Young Adult | 2016 |
The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Topics: Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Compounding; Female; Health Status; Humans; Male; Psoriasis; Quality of Life | 2016 |
A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Betamethasone; Calcitriol; China; Clinical Protocols; Data Interpretation, Statistical; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Models, Statistical; Psoriasis; Quality of Life; Recurrence; Remission Induction; Research Design; Skin; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2016 |
Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Gels; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Pruritus; Psoriasis; Remission Induction; Republic of Korea; Severity of Illness Index | 2017 |
Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Combinations; Finland; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammation Mediators; Interleukin-17; Interleukin-23; Psoriasis; Receptors, Glucocorticoid; Signal Transduction; Skin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
Topics: Adult; Aerosols; Betamethasone; Betamethasone Valerate; Calcitriol; Dermatologic Agents; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Single-Blind Method; Treatment Outcome | 2017 |
Treatment of nail psoriasis with Pulse Dye Laser plus calcipotriol betametasona gel vs. Nd:YAG plus calcipotriol betamethasone gel: An intrapatient left-to-right controlled study.
Topics: Adult; Aged; Betamethasone; Calcitriol; Combined Modality Therapy; Drug Combinations; Female; Gels; Humans; Lasers, Dye; Lasers, Solid-State; Low-Level Light Therapy; Male; Middle Aged; Nail Diseases; Prospective Studies; Psoriasis; Treatment Outcome | 2017 |
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2017 |
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Physician-Patient Relations; Psoriasis; Quality of Life; Treatment Outcome; Young Adult | 2017 |
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.
Topics: Administration, Topical; Adolescent; Adult; Betamethasone; Calcitriol; Cross-Over Studies; Female; Humans; Male; Middle Aged; Patient Compliance; Patient Preference; Prospective Studies; Psoriasis; Severity of Illness Index; Surveys and Questionnaires; Young Adult | 2017 |
A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome; Water Loss, Insensible | 2017 |
Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Humans; Medication Adherence; Mobile Applications; Psoriasis; Single-Blind Method | 2018 |
A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Mobile Applications; Psoriasis; Reminder Systems; Severity of Illness Index; Smartphone; Time Factors; Treatment Outcome; Young Adult | 2018 |
Therapeutic equivalence of two formulations of calcipotriol-betamethasone ointment: a multicentre, randomized, double-blind study in adult patients with chronic plaque psoriasis.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Double-Blind Method; Drug Combinations; Drugs, Generic; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Topics: Absenteeism; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Gels; Humans; Medication Adherence; Middle Aged; Pruritus; Psoriasis; Quality of Life; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2018 |
Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo.
Topics: Acupuncture Therapy; Administration, Cutaneous; Adolescent; Adult; Betamethasone; Calcitriol; Child; Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Needles; Skin; Tacrolimus; Treatment Outcome; Vitiligo; Young Adult | 2019 |
Calcipotriol/betamethasone ointment compared to narrow-band UVB in plaque psoriasis: first clinical and ultrasonographic study.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Ointments; Prospective Studies; Psoriasis; Recurrence; Treatment Outcome; Ultrasonography; Ultraviolet Therapy; Young Adult | 2019 |
A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Biological Therapy; Calcitriol; Dermatologic Agents; Drug Compounding; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2018 |
Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Female; Humans; Keratolytic Agents; Male; Middle Aged; Ointments; Psoriasis; Severity of Illness Index; Single-Blind Method; Tretinoin; Young Adult | 2018 |
The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees
Topics: Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Elbow Joint; Female; Humans; Knee Joint; Male; Middle Aged; Pilot Projects; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial.
Topics: Acupressure; Adolescent; Adult; Aged; Betamethasone; Calcitriol; Ear; Humans; Middle Aged; Ointments; Outcome Assessment, Health Care; Psoriasis; Randomized Controlled Trials as Topic; Young Adult | 2019 |
Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Body Mass Index; Body Weight; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Obesity; Ointments; Psoriasis; Severity of Illness Index | 2019 |
Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatitis, Allergic Contact; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Nickel; Patch Tests | 2020 |
Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.
Topics: Adolescent; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Scalp; Treatment Outcome | 2020 |
Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.
Topics: Adolescent; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2020 |
Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis:\
A Post-Hoc Analysis
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Young Adult | 2020 |
Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized cl
Topics: Adult; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Humans; Male; Prospective Studies; Psoriasis; Treatment Outcome | 2021 |
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Body Surface Area; Calcitriol; Data Interpretation, Statistical; Dermatologic Agents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome | 2020 |
Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data
Topics: Administration, Topical; Adolescent; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2020 |
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Secondary Prevention; Time Factors; Treatment Outcome; Young Adult | 2021 |
Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aerosols; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide; Treatment Outcome; Visual Analog Scale | 2020 |
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled
Topics: Adult; Aged; Anti-Inflammatory Agents; Asian People; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gels; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Scalp Dermatoses; Solutions; Treatment Outcome | 2020 |
Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Nausea; Pilot Projects; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome; Young Adult | 2020 |
Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery for Nail Psoriasis.
Topics: Administration, Topical; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Humans; Lasers, Dye; Male; Middle Aged; Nail Diseases; Prospective Studies; Psoriasis; Young Adult | 2021 |
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Skin Cream; Treatment Outcome | 2021 |
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Topics: Administration, Cutaneous; Adult; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
Topics: Aerosols; Betamethasone; Body Surface Area; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Maintenance Chemotherapy; Psoriasis; Quality of Life; Recurrence; Remission Induction; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2021 |
Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
Topics: Aerosols; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Finland; Humans; Psoriasis; Recurrence; Treatment Outcome | 2022 |
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Recurrence; Treatment Outcome | 2022 |
Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Patient Reported Outcome Measures; Psoriasis; Quality of Life; Treatment Outcome | 2022 |
Impact of topical emollient, steroids alone or combined with calcipotriol, on the immune infiltrate and clinical outcome in psoriasis.
Topics: Betamethasone; Calcitriol; Emollients; Humans; Inflammation; Interleukin-17; Ointments; Psoriasis | 2022 |
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Emollients; Humans; Psoriasis; Treatment Outcome | 2023 |
137 other study(ies) available for betamethasone and calcitriol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of betamethasone on plasma and intestinal calcium binding protein and on 25-hydroxyvitamin D3 metabolism in the pig.
Topics: Animals; Betamethasone; Body Weight; Calcifediol; Calcitriol; Calcium; Calcium-Binding Proteins; Intestinal Absorption; Intestine, Small; Kinetics; S100 Calcium Binding Protein G; Swine | 1986 |
Effects of acute and chronic treatment with glucocorticoids on the intestinal absorption of calcium and phosphate and on plasma 1,25-dihydroxyvitamin D levels in pigs.
Topics: Animals; Betamethasone; Calcitriol; Calcium; Drug Administration Schedule; Hydrocortisone; Intestinal Absorption; Phosphates; Swine | 1985 |
Hormones and the intestinal absorption of calcium and phosphate in man.
Topics: Acromegaly; Adolescent; Adult; Betamethasone; Calcitriol; Calcium; Cushing Syndrome; Female; Humans; Hyperparathyroidism; Hypoparathyroidism; Intestinal Absorption; Kidney; Male; Middle Aged; Phosphates; Prednisone | 1984 |
The effect of betamethasone on duodenal calcium absorption and 1,25-dihydroxy vitamin D3 production in the chick.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Animals; Betamethasone; Bone and Bones; Calcitriol; Calcium; Chickens; Duodenum; Intestinal Absorption; Kidney; Minerals; Phosphates | 1983 |
Enhancement of the granulation tissue formation in hairless mice by a potent vitamin D receptor agonist--KH 1060.
Topics: Animals; Betamethasone; Calcitriol; Cell Division; Connective Tissue; Gene Expression; Granulation Tissue; Mice; Mice, Hairless; Polymerase Chain Reaction; Receptors, Calcitriol; RNA, Messenger; Transforming Growth Factor beta; Wound Healing | 1994 |
Ultrastructure of murine dermis following topical application of the vitamin D3 analogue KH-1060.
Topics: Animals; Betamethasone; Calcitriol; Collagen; Female; Fibroblasts; Glycosaminoglycans; Immunosuppressive Agents; Mice; Mice, Hairless; Microscopy, Electron; Skin | 1997 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis | 2000 |
Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats.
Topics: Animals; Betamethasone; Calcitriol; Dermatitis, Allergic Contact; Ear; Enzyme-Linked Immunosorbent Assay; Glucocorticoids; Immunosuppressive Agents; Interferon-gamma; Interleukin-4; Oxazolone; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Tacrolimus | 2002 |
[New ointment with vitamin D derivative and corticoid. Psoriasis therapy combined].
Topics: Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Humans; Ointments; Psoriasis | 2003 |
Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Confidence Intervals; Data Interpretation, Statistical; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Multicenter Studies as Topic; Patient Compliance; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors | 2003 |
[Daivobet: new therapeutic management for psoriasis. Introduction].
Topics: Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Humans; Ointments; Psoriasis; Treatment Outcome | 2004 |
[Daivobet: from concept to medication].
Topics: Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Design; Humans; Placebos; Psoriasis; Treatment Outcome | 2004 |
Bioavailability of betamethasone dipropionate when combined with calcipotriol.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Biological Availability; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Interactions; Humans; Male; Middle Aged; Pilot Projects; Psoriasis | 2004 |
Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle.
Topics: Administration, Topical; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Denmark; Drug Combinations; Drug Compounding; Drug Design; Humans; Ointments; Permeability; Pharmaceutical Vehicles; Skin; Solubility | 2004 |
Once daily vs. twice daily applications of topical treatments in psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Psoriasis | 2005 |
Treatment of guttate psoriasis with a new two-compound product containing calcipotriol and betamethasone dipropionate.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Ointments; Psoriasis | 2005 |
Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis.
Topics: Adult; Betamethasone; Calcitriol; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2006 |
A betamethasone-calcipotriene combination for psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clinical Trials as Topic; Dermatologic Agents; Drug Combinations; Humans; Psoriasis | 2006 |
Generalized pustular psoriasis complicated by acute respiratory distress syndrome.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Male; Middle Aged; Psoriasis; Respiratory Distress Syndrome | 2006 |
Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product.
Topics: Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2007 |
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
Topics: Anti-Inflammatory Agents; Betamethasone; Biological Products; Calcitriol; Dermatologic Agents; Drug Administration Routes; Humans; Psoriasis; Severity of Illness Index; Skin Diseases; Treatment Outcome | 2007 |
Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antigens, CD; Betamethasone; Biopsy; Calcitriol; Cell Proliferation; Dermatologic Agents; Drug Therapy, Combination; Epidermis; Female; Humans; Keratinocytes; Low-Level Light Therapy; Male; Ointments; Psoriasis; Skin; T-Lymphocytes; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Treatment Outcome | 2007 |
Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris.
Topics: Administration, Topical; Adrenal Cortex Hormones; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Humans; Ointments; Psoriasis | 2007 |
Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study.
Topics: Betamethasone; Calcitriol; Drug Combinations; Humans; Multicenter Studies as Topic; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic | 2007 |
First case series on the use of calcipotriol-betamethasone dipropionate for morphoea.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Middle Aged; Scleroderma, Localized; Treatment Outcome | 2007 |
Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality-Adjusted Life Years; Scotland; State Medicine; Treatment Outcome | 2007 |
Acrodermatitis continua of Hallopeau on toes successfully treated with a two-compound product containing calcipotriol and betamethasone dipropionate.
Topics: Acrodermatitis; Administration, Topical; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Psoriasis; Skin | 2007 |
Clinical pitfalls: a painful nail enlargement.
Topics: Betamethasone; Calcitriol; Female; Humans; Middle Aged; Nail Diseases; Psoriasis; Ultrasonography | 2008 |
Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Middle Aged; Phenylalanine; Photochemotherapy; Severity of Illness Index; Tacrolimus; Treatment Outcome; Ultraviolet Therapy; Vitiligo; Young Adult | 2008 |
Steroid swapping between friends: adrenal suppression secondary to psoriasis treatment.
Topics: Acitretin; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Friends; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Prescription Drugs; Psoriasis | 2009 |
[Update of the topical treatment of psoriasis].
Topics: Administration, Topical; Betamethasone; Calcitriol; Drug Therapy, Combination; Humans; Psoriasis | 2009 |
Generalized pustular psoriasis (von Zumbusch) following the use of calcipotriol and betamethasone dipropionate ointment: a report of two cases.
Topics: Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Eruptions; Female; Humans; Middle Aged; Psoriasis | 2009 |
Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Gels; Humans; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2009 |
Iatrogenic adrenal insufficiency associated with calcipotriol-betamethasone topical combination in psoriasis.
Topics: Adrenal Insufficiency; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Psoriasis | 2010 |
Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Topics: Adiponectin; Adult; Betamethasone; Biomarkers; C-Reactive Protein; Calcitriol; Cardiovascular Diseases; Combined Modality Therapy; Dermatologic Agents; Follow-Up Studies; Glucocorticoids; Humans; Lipid Metabolism; Lipids; Longitudinal Studies; Male; Middle Aged; Oxidative Stress; Psoriasis; PUVA Therapy; Risk Factors; Severity of Illness Index; Ultraviolet Therapy | 2010 |
Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Th17 Cells; Treatment Outcome | 2011 |
The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Drug Combinations; Humans; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Treatment Outcome | 2011 |
Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-gel): results.
Topics: Administration, Topical; Adult; Aged; Betamethasone; Calcitriol; Cohort Studies; Dermatologic Agents; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Scalp Dermatoses; Surveys and Questionnaires | 2011 |
Erythroid disturbances before and after treatment of Portuguese psoriasis vulgaris patients: a cross-sectional and longitudinal study.
Topics: Adult; Betamethasone; Calcitriol; Cross-Sectional Studies; Dermatologic Agents; Erythroid Cells; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neutrophil Activation; Oxidative Stress; Photochemotherapy; Psoriasis; Ultraviolet Therapy | 2012 |
Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemistry, Pharmaceutical; Dermatologic Agents; Drug Combinations; Drug Compounding; Female; Gels; Humans; Male; Ointments; Psoriasis; Scalp; Treatment Outcome; Young Adult | 2013 |
Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo.
Topics: Adult; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Face; Female; Humans; Male; Middle Aged; Ointments; Treatment Outcome; Vitiligo | 2011 |
Linear psoriasis.
Topics: Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Diagnosis, Differential; Drug Combinations; Humans; Male; Psoriasis; Skin Diseases | 2012 |
A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatitis, Atopic; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Infant; Male; Psoriasis; Ultraviolet Therapy | 2012 |
Trends in older adult psoriasis outpatient health care practices in the United States.
Topics: Administration, Cutaneous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Betamethasone; Calcitriol; Clobetasol; Coal Tar; Dermatologic Agents; Dermatology; Etanercept; Family Practice; Female; Fluocinolone Acetonide; Glucocorticoids; Health Care Surveys; Humans; Immunoglobulin G; Immunologic Factors; Internal Medicine; Keratolytic Agents; Male; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Receptors, Tumor Necrosis Factor; United States; Young Adult | 2012 |
Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Gels; Humans; Psoriasis; Quality of Life; Scalp Dermatoses; Time Factors | 2012 |
Whole field laser Doppler imaging of the microcirculation in psoriasis and clinically unaffected skin.
Topics: Aged; Betamethasone; Calcitriol; Dermatologic Agents; Female; Heart Rate; Humans; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Psoriasis; Skin; Treatment Outcome | 2014 |
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |
Nail psoriasis masqueraded by secondary infection with Rhodotorula mucilaginosa.
Topics: Acitretin; Adult; Anti-Inflammatory Agents; Antifungal Agents; Betamethasone; Calcitriol; Coinfection; Dermatologic Agents; Humans; Itraconazole; Keratolytic Agents; Male; Microbiological Techniques; Molecular Diagnostic Techniques; Nails; Onychomycosis; Psoriasis; Rhodotorula; Treatment Outcome | 2013 |
The impact of topical calcipotriol and betamethasone on human beta-defensin 2 expression and serum level in psoriatic patients.
Topics: Adult; Betamethasone; Calcitriol; Defensins; Humans; Middle Aged; Psoriasis | 2013 |
Patterns of vitamin D analog use for the treatment of psoriasis.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Cross-Sectional Studies; Dermatologic Agents; Female; Glucocorticoids; Health Care Surveys; Humans; Male; Practice Patterns, Physicians'; Psoriasis; Time Factors; United States; Vitamin D | 2013 |
The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Animals; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Psoriasis; Vitamin D | 2013 |
Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs.
Topics: Adolescent; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Scalp Dermatoses; Young Adult | 2013 |
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.
Topics: Adolescent; Adult; Aged; Betamethasone; Calcitriol; Drug Administration Schedule; Female; Gels; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Prospective Studies; Psoriasis; Quality of Life; Young Adult | 2014 |
Prescription size and adherence in the management of psoriasis: is the more, the better?
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Attitude of Health Personnel; Betamethasone; Calcitriol; Clobetasol; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Drug Prescriptions; Gels; Humans; Immunosuppressive Agents; Medication Adherence; Practice Patterns, Physicians'; Psoriasis | 2014 |
Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort.
Topics: Adolescent; Betamethasone; Calcitriol; Child; Child, Preschool; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Ointments; Prospective Studies; Psoriasis; Quality of Life; Treatment Outcome | 2014 |
Simple onycholysis: a diagnosis of exclusion.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Onycholysis | 2014 |
Reply: To PMID 23957979.
Topics: Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Female; Humans; Male; Onycholysis | 2014 |
Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Gels; Humans; Male; Middle Aged; Ointments; Pharmacovigilance; Product Surveillance, Postmarketing; Psoriasis; Scalp Dermatoses; Treatment Outcome | 2014 |
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy.
Topics: Animals; Anti-Inflammatory Agents; Atrophy; Betamethasone; Calcitriol; Cells, Cultured; Drug Combinations; Drug Interactions; Extracellular Matrix; Female; Fibroblasts; Gene Expression Regulation; Humans; Keratinocytes; Organ Culture Techniques; Skin; Swine; Swine, Miniature | 2014 |
Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice.
Topics: Administration, Topical; Adrenal Cortex Hormones; Betamethasone; Calcitriol; Cholecalciferol; Clinical Trials as Topic; Drug Combinations; Evidence-Based Medicine; Guideline Adherence; Humans; Long-Term Care; Psoriasis | 2014 |
Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis.
Topics: Administration, Topical; Animals; Betamethasone; Calcitriol; Cell Line; Cell Proliferation; Dermis; Diglycerides; Drug Carriers; Drug Combinations; Drug Evaluation, Preclinical; Drug Stability; Epidermis; Gels; Humans; Mice, Inbred BALB C; Nanoparticles; Psoriasis; Rats, Sprague-Dawley; Solubility | 2014 |
Calcipotriene-betamethasone dipropionate topical suspension in the management of psoriasis: a status report on available data with an overview of practical clinical application.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Dermatology; Drug Combinations; Evidence-Based Medicine; Humans; Psoriasis; Suspensions; Treatment Outcome | 2014 |
Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Child; Child, Preschool; Drug Combinations; Female; Humans; Male; Prospective Studies; Psoriasis; Quality of Life; Scalp Dermatoses; Severity of Illness Index | 2015 |
Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment.
Topics: Adalimumab; Administration, Topical; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betamethasone; Biopsy; Calcitriol; CD4-Positive T-Lymphocytes; Female; Forkhead Transcription Factors; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Ointments; Psoriasis; Skin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2015 |
Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists' preferences for alternative treatment options.
Topics: Administration, Cutaneous; Attitude of Health Personnel; Betamethasone; Calcitriol; Dermatologic Agents; Dermatology; Drug Combinations; Glucocorticoids; Health Care Surveys; Humans; Italy; Medication Adherence; Practice Patterns, Physicians'; Psoriasis; Quality of Life | 2015 |
Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.
Topics: Administration, Cutaneous; Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Pruritus; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Suspensions; Treatment Outcome | 2014 |
Calcipotriol/betamethasone dipropionate ointment compared with tacrolimus ointment for the treatment of erosive pustular dermatosis of the scalp: a split-lesion comparison.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Immunosuppressive Agents; Ointments; Scalp Dermatoses; Tacrolimus | 2015 |
A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.
Topics: Aerosols; Betamethasone; Calcitriol; Calcium; Dermatologic Agents; Drug Combinations; Female; Homeostasis; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Psoriasis | 2016 |
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Child; Dermatologic Agents; Drug Combinations; Female; Gels; Humans; Male; Medication Adherence; Middle Aged; Ointments; Patient Satisfaction; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Time Factors; Young Adult | 2015 |
Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Emulsions; Female; Glucocorticoids; Humans; Male; Middle Aged; Mometasone Furoate; Patient Acceptance of Health Care; Patient Compliance; Patient Preference; Prospective Studies; Psoriasis; Quality of Life; Scalp Dermatoses | 2016 |
Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Topics: Adrenal Cortex Hormones; Betamethasone; Calcitriol; Cell Communication; Cell Differentiation; Cells, Cultured; Cytokines; Drug Therapy, Combination; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation Mediators; Keratinocytes; Langerhans Cells; Phenotype; Psoriasis; Receptors, Calcitriol; Signal Transduction; Th17 Cells; Tissue Culture Techniques | 2016 |
Short-term chemical pretreatment cannot replace curettage in photodynamic therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Curettage; Dermatologic Agents; Drug Therapy, Combination; Female; Fluorescence; Healthy Volunteers; Humans; Keratolytic Agents; Male; Middle Aged; Ointments; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Salicylic Acid; Young Adult | 2016 |
[Topical psoriasis therapy becomes more tolerable].
Topics: Administration, Topical; Betamethasone; Calcitriol; Drug Combinations; Gels; Humans; Psoriasis | 2016 |
Case of de novo psoriasis possibly triggered by nivolumab.
Topics: Administration, Cutaneous; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Betamethasone; Calcitriol; Drug Combinations; Humans; Male; Melanoma; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Programmed Cell Death 1 Receptor; Psoriasis; Signal Transduction; Th1 Cells; Th17 Cells | 2017 |
Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris.
Topics: Adolescent; Adult; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Gels; Greece; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2016 |
Disseminated superficial actinic porokeratosis (DSAP): significant improvement after local administration of calcipotriol/betamethasone gel?
Topics: Administration, Topical; Aged, 80 and over; Betamethasone; Calcitriol; Drug Administration Schedule; Drug Therapy, Combination; Female; Gels; Humans; Keratosis, Actinic; Leg Dermatoses; Porokeratosis; Treatment Outcome | 2017 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Aged; Ambulatory Care Facilities; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Biological Products; Calcitriol; Cost of Illness; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Female; Glucocorticoids; Humans; Japan; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis.
Topics: Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Gels; Humans; Markov Chains; Netherlands; Ointments; Phototherapy; Psoriasis; Severity of Illness Index | 2017 |
Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Female; Humans; Linear Models; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Young Adult | 2017 |
Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Topics: Adolescent; Adult; Aged; Anxiety; Betamethasone; Calcitriol; Depression; Dermatologic Agents; Female; Health Status; Health Surveys; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Psoriasis; Psychometrics; Quality of Life; Young Adult | 2017 |
Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
Topics: Betamethasone; Biological Products; Budgets; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Models, Econometric; Psoriasis; Severity of Illness Index; United States | 2017 |
A combination of low-dose systemic etretinate and topical calcipotriol/betamethasone dipropionate treatment for hyperkeratosis and itching in Olmsted syndrome associated with a TRPV3 mutation.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Betamethasone; Calcitriol; Drug Combinations; Drug Therapy, Combination; Etretinate; Humans; Keratolytic Agents; Keratosis; Male; Ointments; Pruritus; Syndrome; Treatment Outcome; TRPV Cation Channels | 2017 |
Patients with male gender or greater body weight use smaller amounts of topical therapy in psoriasis.
Topics: Administration, Topical; Adult; Betamethasone; Body Weight; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult | 2018 |
Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study.
Topics: Adiponectin; Administration, Cutaneous; Aerosols; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Chemokine CCL22; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Interleukin-17; Male; Middle Aged; Psoriasis; Treatment Outcome | 2018 |
Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris.
Topics: Adult; Aged; Aged, 80 and over; Betamethasone; Calcitriol; Calcium; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Incidence; Japan; Male; Middle Aged; Ointments; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis.
Topics: Adalimumab; Administration, Cutaneous; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Lymphocytosis; Lymphopenia; Male; Middle Aged; Ointments; Psoriasis; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th17 Cells; Ultraviolet Therapy | 2018 |
A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
Topics: Aerosols; Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Humans; Ointments; Psoriasis; Quality-Adjusted Life Years | 2018 |
Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions.
Topics: Adult; Aerosols; Aged; Anti-Inflammatory Agents; Betamethasone; Body Surface Area; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2017 |
Improvement in facial discoid dermatosis with calcipotriol/betamethasone ointment and low-dose acitretin.
Topics: Acitretin; Asian People; Betamethasone; Calcitriol; Combined Modality Therapy; Dermatologic Agents; Drug Combinations; Facial Dermatoses; Female; Glucocorticoids; Humans; Keratolytic Agents; Middle Aged; Ointments; Treatment Outcome | 2018 |
Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Self Report; Treatment Outcome; Young Adult | 2018 |
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Calcitriol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Dyssomnias; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pruritus; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Single-Blind Method; Visual Analog Scale | 2019 |
Validated Chromatographic Methods for Simultaneous Determination of Calcipotriol Monohydrate and Betamethasone Dipropionate in the Presence of Two Dosage Form Additives.
Topics: Betamethasone; Calcitriol; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Limit of Detection; Linear Models; Ointments; Reproducibility of Results | 2019 |
A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Clinical Decision-Making; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Dermatologic Agents; Disease Progression; Drug Compounding; Drug Costs; Glucocorticoids; Humans; Models, Economic; Office Visits; Ointments; Phototherapy; Psoriasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sweden; Time Factors; Treatment Outcome | 2019 |
Sociodemographic factors do not have a large influence on adherence to topical treatment in patients with psoriasis.
Topics: Administration, Cutaneous; Age Factors; Betamethasone; Calcitriol; Denmark; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Medication Adherence; Middle Aged; Psoriasis; Self Report; Severity of Illness Index; Sex Factors; Socioeconomic Factors | 2019 |
Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
Topics: Administration, Topical; Adult; Aerosols; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Hand; Humans; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Prospective Studies; Psoriasis; Severity of Illness Index; Young Adult | 2019 |
Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Topics: Administration, Cutaneous; Betamethasone; Calcitriol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2019 |
The Role of Combination Calcipotriol plus Betamethasone Dipropionate Gel in the Treatment of Moderate-to-Severe Scalp Seborrhoeic Dermatitis.
Topics: Adult; Betamethasone; Calcitriol; Dermatitis, Seborrheic; Drug Combinations; Female; Humans; Malaysia; Male; Retrospective Studies; Scalp; Treatment Outcome | 2018 |
Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
Topics: Administration, Cutaneous; Animals; Betamethasone; Calcitriol; Cytokines; Dermatologic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucocorticoids; Humans; Imiquimod; Mice; Ointments; Psoriasis; Skin; Th1 Cells; Th17 Cells | 2020 |
A novel vehicle for the treatment of psoriasis.
Topics: Administration, Cutaneous; Adult; Aerosols; Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2020 |
Rapid remission with calcipotriol betamethasone in refractory Fox-Fordyce disease.
Topics: Adult; Axilla; Betamethasone; Calcitriol; Female; Fox-Fordyce Disease; Hair Removal; Humans | 2020 |
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2021 |
A case of disseminated molluscum contagiosum caused by topical calcipotriol/betamethasone in an immunocompetent adult.
Topics: Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Eczema; Glucocorticoids; Humans; Male; Molluscum Contagiosum; Skin | 2020 |
Sensitivity of Different In Vitro Performance Tests and Their In Vivo Relevance for Calcipotriol/Betamethasone Ointment.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Evaluation; Drug Liberation; Female; Humans; In Vitro Techniques; Male; Ointments; Psoriasis; Random Allocation; Therapeutic Equivalency | 2020 |
Extragenital lichen sclerosus successfully treated by topical maxacalcitol/betamethasone butyrate propionate.
Topics: Administration, Topical; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Lichen Sclerosus et Atrophicus; Middle Aged; Neck; Skin | 2020 |
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel.
Topics: Administration, Oral; Aged; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Combinations; Drug Resistance; Female; Gels; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra-patient, left-to-right prospective study.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Lasers, Dye; Prospective Studies; Psoriasis; Treatment Outcome | 2020 |
Shear wave elastography and microvascular ultrasound in response evaluation to calcipotriol+betamethasone foam in plaque psoriasis.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Feasibility Studies; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome; Ultrasonography; Young Adult | 2021 |
Papular acantholytic dyskeratosis.
Topics: Acantholysis; Betamethasone; Calcitriol; Female; Humans; Keratosis; Middle Aged; Skin Diseases, Papulosquamous; Treatment Outcome | 2021 |
Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Treatment Outcome | 2020 |
Grover's disease successfully treated with calcipotriene/betamethasone dipropionate ointment.
Topics: Acantholysis; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Ichthyosis; Ointments; Psoriasis | 2020 |
Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam for Plaque Psoriasis in Adolescents Aged 12-17 Years.
Topics: Administration, Cutaneous; Adolescent; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Psoriasis; Treatment Outcome | 2020 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Hailey-Hailey disease treated successfully with calcipotriol plus betamethasone dipropionate aerosol foam: A case report.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pemphigus, Benign Familial; Psoriasis; Treatment Outcome | 2021 |
Efficacy of topical calcipotriol betamethasone dipropionate as a new adjuvant therapy to follicular unit extraction technique in treatment of stable vitiligo: clinical, dermoscopic and immunohistological study.
Topics: Betamethasone; Calcitriol; Combined Modality Therapy; Humans; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2021 |
Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Treatment Outcome | 2021 |
Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Quality of Life; Treatment Outcome | 2021 |
Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Pituitary-Adrenal System; Psoriasis; Treatment Outcome | 2021 |
Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective.
Topics: Betamethasone; Calcitriol; Cost-Benefit Analysis; Dermatologic Agents; Drug Combinations; Germany; Humans; Patient Satisfaction; Psoriasis; Quality of Life; Spain; Treatment Outcome | 2021 |
Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Ointments; Psoriasis; Treatment Outcome | 2021 |
A real-world, observational study on the effectiveness with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece: the CELSUS study.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Greece; Humans; Psoriasis; Treatment Outcome | 2021 |
Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Evaluation; Humans; Psoriasis; Treatment Outcome | 2021 |
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.
Topics: Adult; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Psoriasis; Treatment Outcome | 2021 |
Patient-reported outcomes with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece. Results from the CELSUS study.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Greece; Humans; Patient Reported Outcome Measures; Psoriasis; Treatment Outcome | 2021 |
Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Dosage Forms; Drug Combinations; Humans; Prospective Studies; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Female; Humans; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2022 |
Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Greece; Humans; Patient Satisfaction; Psoriasis; Severity of Illness Index; Treatment Outcome | 2022 |
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Pilot Projects; Psoriasis; Thalidomide; Treatment Outcome | 2022 |
The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions.
Topics: Betamethasone; Calcitriol; Humans; Immunologic Memory; Interleukin-17; Psoriasis; Recurrence | 2022 |
An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.
Topics: Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome | 2022 |
Fractional CO 2 Laser versus Fractional CO 2 Laser Plus Betamethasone/Calcipotriol Ointment in the Treatment of Nail Psoriasis.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Humans; Nail Diseases; Ointments; Psoriasis; Treatment Outcome | 2023 |
INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment.
Topics: Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Emollients; Excipients; Humans; Psoriasis; Treatment Outcome | 2023 |